1 The Importance of Following the PROTOCOL in Clinical Trials
2 Presentation Objectives: Upon completion of this presentation, participants will be able to: Describe the following terms: Protocol, Protocol Deviation, Protocol Violation, Form FDA-1572, Protocol Exception Understand the importance of following the clinical trial protocol to exact specifications Create a list of questions that should be answered by the sponsor or trial organizers prior to patient enrollment.
3 PROTOCOL: Definition ICH Guidelines, E6: Good Clinical Practice A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial html
4 PROTOCOL: Definition 21 CFR Part A protocol must contain: A statement of the objectives and purpose of the study. The criteria for patient inclusion / exclusion as well as an estimate of the number of patients to be studied. A description of the design of the study, including the kind of control group to be used, if any, and a description of methods to be used to minimize bias on the part of subjects, investigators, and analysts.
5 PROTOCOL: Definition (cont) The method for determining the dose(s) to be administered, the planned maximum dosage, and the duration of individual patient exposure to the drug. A description of the observations and measurements to be made to fulfill the objectives of the study. A description of clinical procedures, laboratory tests, or other measures to be taken to monitor the effects of the drug in human subjects and to minimize risk.
6 Control of Investigational Drug 21 CFR Control of the investigational drug. An investigator shall administer the drug only to subjects under the investigator's personal supervision or under the supervision of a subinvestigator responsible to the investigator. The investigator shall not supply the investigational drug to any person not authorized to receive it. Sec General responsibilities of investigators. An investigator is responsible for the control of drugs under investigation.
7 Control of Investigational Drug Sec Investigator recordkeeping and record retention. Disposition of drug. An investigator is required to maintain adequate records of the disposition of the drug, including dates, quantity, and use by subjects. If the investigation is terminated, suspended, discontinued, or completed, the investigator shall return the unused supplies of the drug to the sponsor, or otherwise provide for disposition of the unused supplies of the drug under
8 General Investigator Responsibilities 21 CFR : General responsibilities of investigators Ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations; Protecting the rights, safety, and welfare of subjects under the investigator's care; Obtain the informed consent of each human subject to whom the drug is administered.
9 Signed Investigator Statement Form FDA-1572 Statement of the investigator Submitted to FDA by the sponsor Must be signed by the investigator Contains the name and address of the IRB, all clinical labs and locations at which the study will be conducted Lists subinvestigators who are under the supervision of the primary (principal) investigator
10 Signed Investigator Statement I agree to conduct the study(ies) in accordance with the relevant, current protocol(s) and will only make changes in a protocol after notifying the sponsor, except when necessary to protect the safety, rights, or welfare of subject.
11 Form FDA
12 Sponsor Responsibilities 21 CFR Selecting investigators and monitors Select only investigators qualified by training and experience as appropriate experts to investigate the drug. Ship investigational new drugs only to investigators participating in the investigation. Ensure the investigation is in accordance with the IND
13 Protocol DEVIATION: Definition Variation from processes or procedures defined in a protocol. Does not preclude the overall evaluability of subject Does not affect the safety of subject
14 Protocol DEVIATION: Examples Examples of a protocol deviation. Patient has lab values out side the range listed in the protocol for eligibility Protocol says images must begin 15 +/- 5 minutes post injection but begins at 22 minutes.
15 Protocol DEVIATION The number of protocol deviations should be minimal Where clinical or technical situation varies from the protocol due to circumstances beyond your control Protocol deviations that involve safety measurements should be reported to the IRB Protocol deviations should not take place in situations where you simply want to do things differently
16 Protocol VIOLATION: Definition A significant departure from processes or procedure May affect the evaluability of the data
17 Protocol VIOLATION: Examples Some examples of Protocol Violation Changing technical parameters of the acquisition Enrolling an ineligible subject Improper informed consent
18 Example 1 You are supposed to inject 10 mci per protocol, and due to the radiopharmacy processing you only have 7.5 mci in the syringe. What do you do? Depending upon the study, the sponsor may provide a protocol exception, or may instruct you to not use that dose because it is too low. Do not simply inject just because the patient is on the table! If the sponsor allows the exception, make sure you have the sponsor provide official documentation stating that it was ok to inject the lesser amount.
19 Avoiding Deviations & Violations If a technical glitch causes a protocol deviation that is out of your control, document the situation in writing (note to file): what happened, what you did, and why you did it. Always include your signature and the date.
20 Avoiding Deviations & Violations Provide education and written information to all imaging technologists that may be participating in the scanning of a research patient. This will help reduce deviations and violations of the protocol. Source documentation will be standardized Sponsor s expectations will be met
21 Avoiding Deviations & Violations Provide a copy of the protocol and technical manual to the technologists in addition to keeping a copy in the department. Reinforce the importance of quality imaging data. Worksheets and checklists are recommended
22 Avoiding Deviations & Violations There may be a long period of time between scanning study participants. Prepare prior to the participants arrival.
23 Avoiding Deviations & Violations If the study protocol is standard of care imaging: It is still important to identify the patient as a study participant. If the study protocol is not standard of care imaging: Review the protocol and the imaging manual. Have all case report forms that need to be filled out at the time of the scan readily available. Confirm the participants appointment and the time of the delivery of the radiopharmaceutical.
24 Protocol AMENDMENT: Definition ICH Guidelines, E6: Good Clinical Practice Protocol Amendment: A written description of a change(s) to, or formal clarification of a protocol html
25 Protocol AMENDMENT: Definition 21 CFR Protocol Amendments A sponsor shall submit a protocol amendment describing any change in a Phase 1 protocol that significantly affects the safety of subjects or any change in a Phase 2 or 3 protocol that significantly affects the safety of subjects, the scope of the investigation, or the scientific quality of the study
26 Protocol AMENDMENT: Definition Examples of changes requiring an amendment under 21 CFR : Any increase in drug dosage or duration of exposure of individual subjects to the drug beyond that in the current protocol, or any significant increase in the number of subjects under study. Any significant change in the design of a protocol (such as the addition or dropping of a control group).
27 Protocol AMENDMENT: Definition The addition of a new test or procedure that is intended to improve monitoring for, or reduce the risk of, a side effect or adverse event; or the dropping of a test intended to monitor safety.
28 Protocol AMENDMENT: Definition Amendments (and revised consent forms) must be approved by the IRB prior to implementation Exception: administrative or clerical amendments can be submitted to the IRB as informational only Amendments are submitted to the FDA by the sponsor Amendments are submitted to the investigator in writing
29 Site Participation Prior to a site participating in a sponsored clinical trial, a general discussion should take place between the sponsor and the imaging personnel. The aim of this discussion is to assess whether the site is capable (i.e. equipment and/or personnel) of properly conducting the study procedures.
30 Site Participation This discussion (or questionnaire) may include information regarding: Site information (address, , fax, phone) Site equipment (scanner, radiopharmacy, phantoms, collimators) Investigator/personnel Regulatory requirements (lab certifications, CVs and medical licenses) Research experience (Phase 1, 2, 3) HIPPA compliance Medical records policies
31 Feasibility Examination Imaging personnel should carefully review the protocol for details on technical procedures. Does the protocol detail the: Scanning parameters Quality control procedures (e.g., calibration) Imaging and radiopharmacy equipment required Specimen handling required (e.g., blood samples) Specialized equipment required (e.g. well counter, centrifuge)
32 Feasibility Examination Questions to consider: Does your site have the proper personnel and equipment to participate in the clinical trial? It is not enough to simply say yes, we do PET/CT in response to a question about whether you can do a sponsored clinical trial!
33 What questions do I ask? Do I have to qualify my PET or PET/CT scanner? Can my site receive or produce the radiopharmaceutical used in the study? How long will the scans and QC take? Is there any specialized equipment (such as a biohazard freezer, centrifuge, well counter) required for the study? Who is responsible for labwork, ECGs, urine collection, or other study parameters?
34 What questions do I ask? How will I be transferring the image data and when does it need to be transferred (i.e. sftp and within what time period)? What imaging data needs to be submitted (e.g., raw data or reconstructions)? What are the file naming procedures (i.e. PET AC, PET NAC, CTAC, etc.) What are the dose ordering procedures? What forms do I use to record data?
35 Sponsor Provided Materials Protocol Technical manual(s) Forms/worksheets for source documentation and image transfer The advantages of a technical manual are: Protocol amendments not required for changes Ease of distributing a specialized document Can be modified based on site-specific needs
36 Implementing the Protocol Reviewing the sponsor s imaging protocol and/or manual is important to determine whether the scanning protocol makes clinical sense. The imaging data should provide information to support or answer the primary goals or the imaging endpoints of the study. If the principle investigator (PI) is not in the imaging department, such as oncology, close communication between department staff is required.
37 Implementing the Protocol What do you do if you have not been given ample opportunity to perform a thorough review of the imaging, QC, or radiopharmacy procedures? Contact the sponsor, CRO, or imaging core lab. Document all communication. s Memos Telephone conversation Keep the study coordinator in the loop.
38 Implementing the Protocol In addition to reviewing the sponsor s protocol and imaging manual, review any CRF s and source document worksheets that you may be responsible for completing at the time of the scan. A CFR (Case Report Form) is a paper or electronic set of questions that is used to collect data in a clinical trial. A source document worksheet is a place where you record raw data.
39 Implementing the Protocol Data that you may be required to provide: Date of scan Dose assay time (pre and post injection) Net administered activity Time of injection Scan start time, end time
40 Queries and Data Clarification If any imaging data is found to be missing or if the data is inaccurate or inconsistent with the imaging protocol, a query or data clarification form may be sent by the sponsor. A query may or may not be a protocol deviation or a protocol violation. A query is used to obtain missing information or to clarify a portion of the imaging data received.
41 Queries and Data Clarification A query may be sent due to: Date of birth in the DICOM header does not match the CRF. Missing images or incomplete submission Time of scan does not match protocol requirements Data is not anonymized in all DICOM headers
42 Documentation It is industry standard and imperative to document all correspondence between the site and the sponsor. It is also good to document all correspondence with the imaging core lab if one is used for the trial. Documentation includes: Memo Phone conversation Note to file
43 Communication It is important to include the study coordinator in all correspondence with the sponsor. Ways to keep the coordinator in the loop : Courtesy copy on all s Courtesy copy on paper correspondence Notify the coordinator of telephone conversations with the sponsor and the results Include the coordinator in all scheduled teleconferences and meetings with the sponsor
44 Department Cooperation/Education Don t underestimate the time it will take for a research protocol. Schedule adequate time for any ancillary procedures that need to take place in the imaging room (vitals, ECG, blood draws, etc.) Inform front desk personnel about any specimen handling questions (such as a patient dropping off urine samples, questionnaires, etc.)
45 Department Cooperation/Education Departmental staff may be required to alter standard department procedures to accommodate a research study. Staff may include: Schedulers Transporters Nurses Administrative Radiation safety
46 Department Cooperation/Education Design a procedure that will notify the nuclear medicine department when a trial participant is scheduled to have their scan. This will give the technologists enough time to perform any mandatory QC prior to the scan. The protocol may require the lab to perform a cross-calibration between the PET scanner and the well counter within a certain amount of days of the scan (blood sampling protocol).
47 Summary The protocol is a specific document that describes the clinical trial in detail. Protocol amendments must be submitted to the IRB before they are implemented. The investigator is responsible for making sure all patients provide written informed consent. The investigator is responsible for control of the investigational product.
48 Summary Imaging procedures may be included in the protocol or a technical manual. Avoid protocol deviations and violations. Don t change any protocol parameters without permission from the sponsor or the sponsor s representative. Document everything, and communicate to everyone.
Subject: ROUTINE MONITORING VISITS Standard Operating Procedure Prepared By: Beaumont Research Coordinating Center, Research Institute PURPOSE Prior Issue Date 8/15/2011 No. 706 Issue Date 4/21/2014 Page
Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010
ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
Orientation Manual for Clinical Research Coordinators Maine Medical Center Research Institute Page 1 of 19 Version 1 (2009) MAINE MEDICAL CENTER RESEARCH INSTITUTE Statement of Mission, Vision, Goals and
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
Data Management DM 401.00 STANDARD OPERATING PROCEDURE FOR Data Management Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell, MD, FACP
CLINICAL RESEARCH PROTOCOL CHECKLIST [taken from ICH GCP : Guidance for Industry, Good Clinical Practice: Consolidated Guidance, Revision 1 (R1) June 1996] ICH GCP, Section 6. CLINICAL TRIAL PROTOCOL AND
Quality Monitoring Checklist Instructions: For each task below, the Quality Monitor indicates in the appropriate column if the Monitor accomplished the task by using the following codes Yes No N/A = Monitor
Effective Date: 09/12/06, 08/02/10, 3/2/11 Title: 1.0 OBJECTIVE: 1.1 This SOP describes the methods and policies for: Handling investigational drug Dispensing investigational drug 1.2. This procedure applies
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
9.0 Protocol Violations, Deviations, and Exceptions 9.1 Definitions Protocol deviation(s): means a minor or administrative departure from the IRBapproved protocol procedures (e.g., the protocol, informed
Tool Summary Sheet Tool: Extramural Essential Documents Binder/File Tabs Purpose: To provide an organizational framework and guidance for filing paper versions of essential study documents (or referencing
Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal
The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial Clinical Research Operations & Regulatory Support (CRORS) Ann Glasse, RN, BSN, MBA Director-CRORS Objectives
Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) U.S. Department of Health and Human Services Food and Drug
FDA Audit Guidelines University of Miami Office of the Vice Provost for Research FDA Audit Guidelines Contents INTRODUCTION 3 VICE PROVOST FOR RESEARCH ROLE IN FDA AUDITS 3 PRE-AUDIT REVIEW 3 INSPECTION
Comprehensive Study Documents List (Biomedical Studies) Investigators conducting human subjects research must maintain study documents in adherence to federal and state regulations, USC policies, and good
Site Initiation and Close Out (Sponsored Clinical Trials) Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 008 Version number: 1 Effective date: 01 June
The Regulations and Regulatory Practices in the US and EU for Amendments During Drug Development May 17, 2011 Beijing, China Alberto Grignolo, Ph.D Corporate Vice President, Global Strategy PAREXEL Consulting
Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for
E DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 - JAN 1 6 2007 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Lawrence S. Kim, M.D.
Investigator Responsibilities in Clinical Research: Insights and helpful hints for researchers ITHS Clinical Research Education Series September 7, 2010 Objectives Understanding the requirements of DHHS
Clinical Trial Budgets Madelene Ottosen, MSN, RN Associate Director, Clinical Trials Resource Center Office of Research and Center for Clinical and Translational Sciences The University of Texas Health
PROTOCOL DEVIATIONS 229 1 of 7 PURPOSE The purpose of this policy is to define protocol deviations and the subsequent actions required by the Principal Investigator (PI) once a protocol deviation occurs
SAMPLE CRA CV Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: email@example.com Education: Masters of Science, Healthcare Administration, Capital City University,
CNE Disclosures Successful Completion: Participants must complete an evaluation form to receive a certificate of completion Contact Hours: 1 contact hour is available to those who meet the successful completion
CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL #  [TITLE] CONTRACT RESEARCH ORGANIZATION SPONSOR [NAME] [ADDRESS] 1 TABLE OF CONTENTS 1. Purpose 3 2. References 3 3. Study Roles and Responsibilities
UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD EMERGENCY MEDICINE RESEARCH EXEMPTION FROM INFORMED CONSENT REQUIREMENTS I. PURPOSE This document outlines the procedures for University
Essential Documents for the Conduct of a Clinical Trial Debra Dykhuis Associate Director RSO Introduction Rationale for choosing this topic AHC movement toward setting GCP (Good Clinical Practice) guidelines
STANDARD OPERATING PROCEDURE Site Initiation and Closeout Standard Operating Procedure Western Health SOP reference 008 Version: 2.0 dated December 2015 Effective Date Review Date Author: Approved by Mr
Clinical Investigator Training Course Investigator Responsibilities in Biomedical Research Covered by FDA Regulations Lisa Zimmerman Objectives Discuss Clinical Investigator Obligations according to FDA
1 CLINICAL TRIAL FEASIBILITY AND CAPACITY PLANNING FORM Clinical trials that run into difficulties often have problems that could have been spotted in advance. An early feasibility assessment helps determine
BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE Jean Toth-Allen, Ph.D. Biophysicist Office of Good Clinical Practice Office of the Commissioner May 14, 2012 1 Overview I. Background why we are
Good Clinical Practice Compliance and the Start-up Company By Robert Schiff, PhD, RAC, CQA, FRAPS, Jodi Pannucci and Mary Ann Weinberg 26 Start-up drug or device companies tend to minimize spending and
STANDARD OPERATING PROCEDURES FOR GOOD CLINICAL PRACTICE UNC OB/GYN (V.1) 9.1.2014 Page i TABLE OF CONTENTS INTRODUCTION. iii ABBREVIATIONS iv GLOSSARY v LISTING OF ATTACHMENTS.... xi I. 1.0 GENERAL ADMINISTRATION
v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,
Quality Management in Clinical Research Julie Doherty MSN, RN Director, Regulatory Compliance Office of Academic Affairs Human Research Protections Office University of Maryland Baltimore March 17, 2016
Effective Budgeting and Contract Negotiations for Clinical Trials Lisa Benson, CCRP, CRCP Director of Research Administration and Sponsored Programs Connecticut Children s Medical Center Workshop Objectives
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Study Start-up
Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors
Role of the Clinical Trial Monitor Dr Christine Maure Monitoring The act of overseeing the progress of a clinical trial, and of ensuring that it is: conducted, recorded, and reported in accordance with
Data Management & Case Report Form Development in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 3, 2015 Marge Good, RN, MPH, OCN Nurse Consultant Division of
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 19, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Related Accreditation Elements: I.1.D., I.1.F., I-2, I.7.B., II.2.E., II.2.F., II.4.A.,
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
Reporting of Adverse Events and Unanticipated Problems Policy date: 12/2011 Purpose The purpose of this policy is to ensure that the review, reporting and analysis of adverse events and unanticipated problems
Centralized vs Onsite Monitoring: A Sponsor s Balancing Act Applying a Risk-based Approach Introduction Since the August 2011 release of the draft guidance document by FDA on a risk-based approach to monitoring
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Data Collection
Roles & Responsibilities of the Research Team Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Introduction All staff involved in clinical
UT Health Science Center at San Antonio Research/Grant Records Agency 1.1 Administrative Records - General 400 DE Experiments and Tests. AV O False SEE section on Medical/Dental - Patient Records, record
PREP Course #6 Research Documentation Presented by: Office of Research Compliance Evelyn Huang, MPH, CCRA, CCRC & Leah Shuchter, MPH CME Disclosure Statement The North Shore LIJ Health System adheres to
CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES 1. Clinical Study Team Principal Investigator Co Principal Investigator (Co PI) Research Coordinator Study Monitor Data manage Sponsor Post Doctoral Scholar
Claim of Exemption Form Page 1 of 6 Principal Investigator: Phone: Project or Protocol Title: Contact Person: Address: Phone: Fax: E-mail: Copy of Principal Investigator s CV attached SPONSOR / FUNDING
Planning for FDA Clinical Site Inspections: Are You at Risk? Catherine M. Anderson, Ph.D., RAC 29 April 2010 Outcome of FDA Inspections (2005-2009)* 5.1 44.5 * Based on 1747 site inspections from 2005-2009
December 13, 2011 Maureen Coyne No industry relationships No financial conflicts of interests Recent experience weighted toward industrysponsored clinical trials Information based on my experiences IRB
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Good Documentation Practices Clinical Research Operations & Regulatory Support Ann Glasse, RN, BSN, MBA Director, Regulatory Support Author: Johanna Stamates, RN, MA, CCRC, CHRC Objectives Recognize the
Guidance for Industry Electronic Source Data in Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
Role of eclinical Systems in FDA Regulated Studies Presented by: Jonathan S. Helfgott Operations Research Analyst Office of Scientific Investigations Disclaimer The contents of this presentation are my
Development of Case Report Forms Introduction to the Principles and Practice of Clinical Research February 12, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
SUBJECT: Principal Investigator Oversight POLICY: RA:HRPP:10.13 DATE EFFECTIVE: PAGE: 1 of 2 I. POLICY The Children s National Medical Center (CNMC) Human Research Protections Program (HRPP) recognizes
IMP management at site Dmitry Semenyuta TOP 5 FDA inspections finding 1999-2009 Center of Drug Evaluation and Research (CDER) Failure to follow the protocol Failure to keep adequate and accurate records
Investigator Initiated Research: Risks, Responsibilities, and Rewards Lori T. Gilmartin BUMC GCRC RSA Support Research Consultant A Growing Concern PhRMA recently reported that spending on IIR had increased
This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,
The Role of the Clinical Trials Nurse Elizabeth Ness, RN, MS Director, Staff Development Center for Cancer Research, NCI Objectives Discuss the clinical trials nurse s involvement in protocol development.
105 CMR 210.000: THE ADMINISTRATION OF PRESCRIPTION MEDICATIONS IN PUBLIC AND PRIVATE SCHOOLS Section 210.001: Purpose 210.002: Definitions 210.003: Policies Governing the Administration of Prescription
UoL Site Initiation Checklist 1. Site Information Site Initiation Visit Method Sponsor Reference Number: On Site Study Name: Teleconference R&I/ R&D Reference Number: Other (specify) Investigator: Study
Research Department STANDARD OPERATING PROCEDURE STH Investigator Archiving of Essential Documentation Generated During Clinical Research SOP Number A127 Version Number V1.3 Effective Date Author Zoe Whiteley
SITE IMAGING MANUAL ACRIN 6698 Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A sub-study of the I-SPY 2 TRIAL Version: 1.0 Date: May 28, 2012
Audit Findings in Clinical Trials: Avoiding the Pitfalls Kris West AVP A.V.P. & Director Office of Research Compliance Top Clinical Trial Audit Finding Areas Informed Consent Process & Documentation Accurate
Notes to File: An Auditor s Perspective Lorrie D. Divers, CCRP, RQAP-GCP Executive Director, Global Quality Assurance & Compliance ACM Medical Laboratory / ACM Global Central Laboratory Clinical Translation
Employee Training Written Directive Program What is a Written Directive? An authorized user s written order for the administration of byproduct material or radiation from byproduct material to a specific